Related Experiment Video
Updated: Jun 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
Y Watanabe1, T Kojima, S Kagawa
1Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan.
Abstract:
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure. MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. Although MPM is an extraordinarily challenging disease to treat, locoregional virotherapy may be useful against this aggressive disease because of the accessibility by intrapleural virus delivery. In this study, we show that telomerase-specific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication. Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into nu/nu mice. A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy. Co-injection of OBP-301 and a replication-defective adenovirus (Ad-S/hep)-expressing heparanase resulted in more profound antitumor effects without apparent toxicity in an orthotopic pleural dissemination model. Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma.
Insights
Oncolytic adenovirus therapy shows promise for malignant pleural mesothelioma (MPM). Combining a telomerase-specific oncolytic adenovirus with a heparanase-expressing adenovirus enhanced antitumor effects in preclinical models.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer with poor prognosis.
- Conventional therapies are often ineffective against MPM.
- Locoregional virotherapy offers a potential treatment strategy due to direct intrapleural delivery.
Purpose of the Study:
- To evaluate the efficacy of a telomerase-specific oncolytic adenovirus (OBP-301) against human mesothelioma cells.
- To investigate the potential of combining OBP-301 with a heparanase-expressing adenovirus to overcome extracellular matrix barriers.
Main Methods:
- In vitro infection and killing of human mesothelioma cells by OBP-301.
- Intrathoracic administration of OBP-301 in a mouse model of human mesothelioma.
- Assessment of viral replication using fluorescence imaging.
- Evaluation of combined OBP-301 and heparanase-expressing adenovirus therapy in an orthotopic pleural dissemination model.
Main Results:
- OBP-301 efficiently infected and replicated within human mesothelioma cells, leading to cell death.
- Intrathoracic OBP-301 treatment significantly reduced tumor burden in mice.
- Combined therapy with OBP-301 and heparanase-expressing adenovirus demonstrated enhanced antitumor effects without observed toxicity.
Conclusions:
- Telomerase-specific oncolytic adenovirus OBP-301 is effective against malignant pleural mesothelioma.
- Dual virotherapy combining OBP-301 with heparanase-expressing adenovirus may improve treatment efficacy by enhancing tumor penetration.
- This combination strategy holds potential for preventing and treating pleural dissemination of MPM.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Human Virome

